JG
EVLO

Jefferies Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Jefferies Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,180
Closed -$307K – 2113
2021
Q3 		$307K Buy
+2,180
New +$432K ﹤0.01% 1363

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's EVLO Position: Q4 2021 in Review

Jefferies Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2021, closing a stake of 2 shares — an estimated $232 sold.

Jefferies Group first reported a position in EVLO in Q3 2021 and held it in 1 quarter. The position peaked at $232 in Q3 2021. 66 funds tracked by Wall St. Rank hold EVLO as of Q4 2021.

  • Jefferies Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 2 Evelo Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $232.
  • Jefferies Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jefferies Group's Evelo Biosciences, Inc. Common Stock position peaked at $232 in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.